These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1909637)

  • 1. Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids.
    Odman B; Ericsson S; Lindmark M; Berglund L; Angelin B
    Eur J Clin Invest; 1991 Jun; 21(3):344-9. PubMed ID: 1909637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
    Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
    Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
    Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary lipids in familial combined hyperlipidaemia: effects of acipimox therapy.
    Ericsson S; Eriksson M; Angelin B
    Eur J Clin Invest; 1990 Jun; 20(3):261-5. PubMed ID: 2114986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
    Rabkin SW; Hayden M; Frohlich J
    Atherosclerosis; 1988 Oct; 73(2-3):233-40. PubMed ID: 3056431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
    Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D
    Atherosclerosis; 1997 Mar; 129(2):231-9. PubMed ID: 9105566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate.
    Mazzella G; Bazzoli F; Villanova N; Simoni P; Festi D; Roda A; Aldini R; Roda E
    Scand J Gastroenterol; 1990 Dec; 25(12):1227-34. PubMed ID: 2274744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
    Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia.
    Liacouras CA; Coates PM; Gallagher PR; Cortner JA
    J Pediatr; 1993 Mar; 122(3):477-82. PubMed ID: 8441109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
    Vázquez M; Zambón D; Hernández Y; Adzet T; Merlos M; Ros E; Laguna JC
    Br J Clin Pharmacol; 1998 Mar; 45(3):265-9. PubMed ID: 9517370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia.
    Eriksson M; Angelin B
    Eur J Clin Invest; 1987 Oct; 17(5):396-401. PubMed ID: 3121342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
    Farnier M
    Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary lipid composition during treatment with different hypolipidaemic drugs.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men.
    Carrella M; Ericsson S; Del Piano C; Angelin B; Einarsson K
    J Intern Med; 1991 Mar; 229(3):241-6. PubMed ID: 2007842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.